FY2024 · ended Dec 31, 2025 · Revenue $2.79M, +1134.5% YoY · Filed Apr 15, 2026
Traws Pharma, Inc. (TRAW) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2024, which ended Dec 31, 2025, it reported revenue of $2.8 million and net income of $9.2 million. Free cash flow was -$20.8 million.
Revenue (TTM)
$2.85M
+1159.3% vs year-ago TTM
Net income (TTM)
$-13.31M
Operating cash flow
$-18.18M
+39.0% vs prior year
Free cash flow
$-20.77M
+37.9% vs prior year
EPS (TTM)
$-1.97
Dividend per share
None
Shares outstanding
15.15M
+49.2% vs prior year
Net cash
—
Operating margin
-554.6%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newtown, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1130598
- Former names
- Onconova Therapeutics, Inc. (until Apr 1, 2024); ONCONOVA THERAPEUTICS INC (until May 26, 2009)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $226,000 | $226,000 | $226,000 | $226,000 |
| Operating income | -$17.9M | -$142.4M | -$20.3M | -$19.6M | -$16.5M |
| Net income | $9.2M | -$166.5M | -$18.9M | -$19.0M | -$16.2M |
| Diluted EPS | $0.82 | -$35.21 | -$22.57 | -$0.91 | -$0.96 |
| Operating cash flow | -$18.2M | -$29.8M | -$17.9M | -$16.3M | -$19.5M |
| Free cash flow | -$20.8M | -$33.4M | -$17.9M | — | — |
| Total assets | $10.6M | $25.0M | $22.7M | $39.4M | $55.5M |
| Total liabilities | $11.2M | $56.6M | $12.0M | $11.1M | $9.4M |
| Stockholders' equity | -$629,000 | -$31.6M | $10.7M | $28.3M | $46.1M |
| Cash and investments | $3.8M | $21.3M | $20.8M | $38.8M | $55.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 23, 2026 | Oct 23, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 31, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Other events
|
Jul 10, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jul 9, 2026 | Jul 8, 2026 |
All 988 Traws Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.